MindMed Announces Publication of Study Comparing the Acute Effects of LSD and Psilocybin in Healthy Subjects

NEW YORK, March 2, 2022 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of brain-based disorders, today announced the peer-reviewed publication of a study directly comparing the acute effects of Lysergic Acid Diethylamide (LSD) and psilocybin in healthy subjects. The data, published in Neuropsychopharmacology and titled, “Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects”, demonstrates that the key differences between LSD and psilocybin are dose-dependent rather than substance-dependent. These findings have the potential to assist with dose finding, trial design and inform future studies evaluating the therapeutic utility of psychedelics.

“The results in this publication continue to expand our knowledge of the differences between LSD and psilocybin with regard to their acute effects, similarities, and dose-equivalence,” said Professor Matthias Liechti M.D., University Hospital Basel, principal investigator of the study. “Although both substances are used as pharmacological tools, there are no modern studies investigating and directly comparing the acute effects of these substances within the same clinical study, using well defined doses and validated psychometric tools. Together, these results suggest that 20 mg psilocybin is equivalent to 100 μg LSD, and 30 mg psilocybin is equivalent to 150 μg LSD, making the dose equivalence of LSD to psilocybin approximately 1:200. Strikingly, there were no qualitative differences in altered states of consciousness across substances, except that the duration of action was shorter for psilocybin.”

Miri Halperin Wernli, Ph.D., Executive President of MindMed, added, “LSD and psilocybin have recently become promising candidates for the treatment of various psychiatric and neurologic disorders, and thus a deeper understanding of their differential subjective effects in humans is needed. This study brings us one step closer to maximizing the therapeutic potential of these molecules, by providing valuable dose finding context and enabling more direct comparisons when interpreting clinical results. These learnings will help guide our rapidly advancing clinical development program, and we look forward to providing updates as we work to bring the benefits of psychedelic-inspired medicines to patients struggling with brain-based disorders.”

In this double-blind, randomized, placebo-controlled, crossover design, researchers evaluated twenty-eight healthy participants who underwent five 25-hour sessions and received placebo, LSD (100 and 200 µg), and psilocybin (15 and 30 mg). Test days were separated by at least 10 days. Outcome measures included self-rating scales for subjective effects, autonomic effects, adverse effects, effect durations, plasma levels of brain-derived neurotrophic factor (BDNF), prolactin, cortisol, and oxytocin, and pharmacokinetics.
Read More